Research programme: casein kinase inhibitors - Oncodesign
Latest Information Update: 02 Dec 2016
At a glance
- Originator Oncodesign Biotechnology
- Class Small molecules
- Mechanism of Action Casein kinase Idelta inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease